hormone therapy

Are there non-glycemic benefits of continuous glucose monitoring?A multinational randomized controlled trial indicates, for what may be the first time, that continuous glucose monitoring (CGM) may have health benefits that go well beyond control of maternal hyperglycemia. Plus: Does postmenopausal HT impact risk of stroke? Also: A study suggests that late puberty affects bone mineral density.
Is genetic testing for cancer survivors underutilized?One study looks at whether or not women with histories of breast or ovarian cancer are receiving necessary genetic testing. Plus: Can in-office hysteroscopy reliably evaluate uterine pathology? Also, researchers say mammographic density changes should be monitored in patients undergoing hormone therapy as a possible indicator of breast cancer.
Hormonal therapies effective for acneHormonal therapies are an effective strategy to improve acne in women but some of these treatments, including birth control pills, are not commonly prescribed.
Antithrombotic therapy to prevent migraine attacks after ASD closureClopidogrel therapy can make a difference after ASD closures.
Menopause counseling hot flash: Persistent VMS more common in African-Americans and more new researchA review of the latest research on the persistence of vasomotor symptoms, the link between hormone therapy and ovarian cancer risk, and the prevalence of substance use in pregnant adolescents.
Benefits and risks of postmenopausal hormone therapy: Two expert opinions
Benefits and risks of postmenopausal hormone therapy: Two expert opinionsThe initial findings from the WHI were concerning, but subsequent detailed analysis and long-term follow-up of women enrolled in these trials have brought perspective.
What’s the impact of hormone therapy on heart health?According to a recent study in Annals of Internal Medicine, hormonal therapy in early menopause may improve some markers of cardiovascular disease (CVD) risk, but not progression of atherosclerosis.
Shorter-duration androgen blockade found efficaciousPatients with high-risk prostate cancer who received 18 months of hormone therapy lived as long as patients treated for 36 months, Canadian researchers report.